Abstract
More than half of all acute myeloid leukaemia (AML) patients are over 60 years. The disease free survival (DFS) and overall survival (OS) rate of these patients is poor. These unsatisfactory results are associated with adverse cytogenetic characteristics, prior myelods-plasia, adverse phenotypic features, MDR and BCL2 overexpression. Furthermore a large fraction of patients achieving CR early relapses. This is due to two factors: acquired tumor cell drug resistance and tumor re-growth. Maintenance therapy could provide a means to keep leukemic growth under control. We enrolled 31 elderly previous responder patients to standard induction therapy to receive maintenance oral IDA 3mg/m2 daily d 1-14 at a 2 weeks interval for a total of 12 cycles or until disease progression. We also evaluated the cell cycle and apoptosis in leukemic cells from PR patients after IDA administration, and as a control from HL60 cell line exposed to IDA and idarubicinol in vitro. DNA analysis showed an increase of G2/M cell frequencies and evidence of apoptosis (sub Gl peak). In CR patients the median DFS and OS was 8 months and 12.5 months respectively. In PR patient the median OS was 9 months. In contrast comparing these results with an historical control group we observe a lower median cumulative OS (3 vs 11 months) and in CR patients a DFS and OS of 4 and 7 months. The treatment was well tolerated. Low haematological and extrahaematological toxicity were observed. In conclusion, longterm low doses of oral IDA would appear valuable as a maintenance regimen for elderly AML patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brinker H (1985): Estimate of overall treatment results in acute non lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treatment Reports,:69: 5–11,.
Cartwright RA & Staines A (1992): Acute leukemias. Epidemiology of Haematological Disease. In:. AT Fleming (eds),. Bailliere’s Clinical Haematology vol: 5, pp:1–26
Lowenberg B (1996): Acute myelogeneus Leukaemia and Myelodysplasia In AT Fleming (eds) Bailliere’s Clinical Haematology, vol.9,pp 147–159.
Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TJ & Frereich EJ (1981): Treatment of patients over 50 years of age with myelogenous leukemia with a combination of rubidazone and cytosine arabnoside, vincristine and prednisolone (ROAP). Blood, 58: 584–591.
Swirsky DM, De Bastos M, Parish SE, Rees JKH & Hayhoe FGJ (1987): Features affecting outcome during remission induction of acute myeloid leukemia in 619 adult patients. British Journal of Haematology, 64: 435–453.
Campos L, Roualt JP, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D (1993): High expression of BCL-2 protein in acute myelogeneous leukemia cells is associated with poor response to chemotherapy. Blood, Vol.81, n°ll: 3091–3096.
Liu Yin JA (1993): Acute myeloid leukemia in elderly: biology and treatment. British Journal of Haematology, vol.8: 361–366.
Baudard M, Marie JP, Cadiou M, Viguié V & Zittoun R (1994): Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. British Journal of Hematology, 86:82–91.
Banker DE, Groudine M, Norwood T & Appelbaum FR (1997): Measurement of spontaneous and therapeutic agent-induced apoptosis. Blood, vol. 89, n°l: 243–255,.
Shiller JC (1996): Post-remission therapy of acute myeloid leukemia in older adults. Leukemia, 10, suppl.l,S18–S20,.
Lowemberg B. (1998): Mitoxantrone versus daunorubicin in induction consolidation chemotherap. The value of low dose Cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. Journal Clinical Oncology, 16,3,872–881
Leoni F, Ciolli S, Pascarella A, Caporale R, Salti F, Cervi L & Rossi Ferrini P (1995): Attenuated-dose idarubicin in acute myeloid leukemia of the elderly: pharmacokinetic study and clinical results. British Journal of Haematology, 90: 169–174.
Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussof B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier RJ, Moon JH (1968): Arabinosyl citosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507,.
Duke RC, Choen JJ (1992): Morphological and biochemical assay of apoptosis in: Coligan JE, Kruis Beack AM (eds) Current Protocols in Immunology. NY: J Willey and Sons pp:3171–6
Kaplan, E. L. & Meier, P. (1958): Nonparametric estimation from incomplete observations. Journal of the American Statistical Association,53: 457–481.
Johnson RE, Ryder WDJ, Liu Yin JA(1995): Validation of a model to predict survival in elderly patients with acute myeloid leukemia. British Journal of Haematology, 90: 954–956.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Musso, M. et al. (2001). Oral Idarubicin in Maintenance Therapy of Acute Myeloid Leukemia. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J., Creutzig, U. (eds) Acute Leukemias VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18156-6_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-18156-6_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62109-3
Online ISBN: 978-3-642-18156-6
eBook Packages: Springer Book Archive